PatientsVille.com Logo

MEMORY IMPAIRMENT and Methotrexate

PatientsVille

MEMORY IMPAIRMENT Symptoms and Causes

Every day, you have different experiences and you learn new things. Your brain cannot store all of that information, so it has to decide what is worth remembering. Memory is the process of storing and then remembering this information. There are different types of memory. Short-term memory stores information for a few seconds or minutes. Long-term memory stores it for a longer period of time.

Memory doesn't always work perfectly. As you grow older, it may take longer to remember things.

It's normal to forget things once in awhile. We've all forgotten a name, where we put our keys, or if we locked the front door. If you are a senior who forget things more often than others your age, you may have mild cognitive impairment. Forgetting how to use your phone or find your way home may be signs of a more serious problem, such as

  • Alzheimer's disease
  • Other types of dementia
  • Stroke
  • Depression
  • Head injuries
  • Blood clots or tumors in the brain
  • Kidney, liver, or thyroid problems
  • Reactions to certain medicines

If you're worried about your forgetfulness, see your health care provider.

NIH: National Institute on Aging

Check out the latest treatments for MEMORY IMPAIRMENT

MEMORY IMPAIRMENT treatment research studies

Methotrexate clinical trials, surveys and public health registries


Find Drug Side Effect reports



Methotrexate Side Effects

Pyrexia (411)
Pancytopenia (356)
Nausea (321)
Pneumonia (304)
Arthralgia (271)
Headache (269)
Injection Site Pain (265)
Rheumatoid Arthritis (260)
Dyspnoea (248)
Mucosal Inflammation (241)
Diarrhoea (238)
Vomiting (231)
Fatigue (223)
Asthenia (198)
Cough (196)
Sepsis (195)
Anaemia (195)
Pain (188)
Renal Failure Acute (177)
Malaise (156)
Febrile Neutropenia (152)
Abdominal Pain (152)
Injection Site Erythema (145)
Pain In Extremity (141)
Convulsion (139)
Rash (139)
Neurotoxicity (138)
Dizziness (131)
Neutropenia (129)
Condition Aggravated (129)
Thrombocytopenia (127)
Toxicity To Various Agents (125)
Oedema Peripheral (121)
Alanine Aminotransferase Increased (121)
Renal Failure (118)
Hypertension (115)
Weight Decreased (114)
Erythema (113)
Interstitial Lung Disease (113)
Stomatitis (108)
Respiratory Failure (108)
Bone Marrow Failure (108)
Leukopenia (104)
Fall (103)
Infection (103)
Aspartate Aminotransferase Increased (99)
Hypotension (95)
Nasopharyngitis (93)
Paraesthesia (93)
Septic Shock (91)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Hi I haven't had any side effects for the past six years of Methotrexate. but recently I am having some stomach discomfort like as soon as i eat something i have the slight discomfort on my abdoman. I take a glass of green leaf juice and i am fine ag

I am 60 Years of age. 8 years ago i was falsely diagnosed with Rheumatoid Arthritis, i was started on Methoblastin 5Mg a week, Was not given Folic Acid and Ranitidine within the 5 months of taking the tablets i developed exposed blood vessels and spo

I have been on methotrexate for almost months and last two weeks have had severe pains at times lower back , It feel like the kidneys because one side hurts at times and in the mornings it is worse. I am 3 days shy of talking another blood test. Is

I just started Methotrexate, I started itching in the same areas where I had experienced itching with the chicken pox 2 years ago. I am a 51 year old female who contracted chicken pox at 49 years old. This frightens me as I know this can cause diss

I only took it for 21 days but in that time, it put me into a full panic attack that lasted almost 8 days after I went off the medication. I had mental confusion, could not speak properly (I knew what I wanted to say but the words would not come out

I was diagnosed with Rheumatoid Arthritis about 4 years ago when I was 13 or 14, they looked at me and said I had it, they didn't do any blood tests and when they did, nothing showed. But they started me on about 5 mg of Methotrexate, Prednisone, and

Im a 44yrs old female who took methotrexate for 2yrs with excellent results and no side effects but had to stop taking it when it started lowering my white cells.

My 27 years of MTX therapy have prevented physical deformity but caused me to have damage to my lungs. I am short of breath on any activity. MTX helped the pain somewhat but at the cost of my lungs? I was never told about this possibility nor told it

Painful cough after 2 days of 1st dose lasting-- to date-- 6 days

What did you have?

As you know, I asked I thought, for the impossible. To refresh you all memory I was very much in love with my best friend (we are both women) well she decided to leave her fianc nine weeks after I ordered your Powerful Love Spell. I am not sure i

since i started novothyral my pulse jumped, and tired,memory problems,my body feels week,unable to do anythyng physical, all in all my life going nowhere since two months ago when i started taking this pill thanks very much a

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

Extreme fatigue, sleeplessness, short term memory and speech difficulties, Edema, weight gain, stumbling, shortness of breath, numbness in both legs, and completely kills ability to achieve orgasm.

<span style='color: #808080;'><b>What do You think about Vision impairment and blindness?</b>

Anon- I would say the weed would cause the MOST memory loss used over time also depending on how strong it is ie, (haze, kush....dro...regs from 60's with seeds) THE STONGER it is the faster the brain cells go! As far as the valium/dia

<strong>Found Celepram effective at the end of the 3rd week. Effectiveness lasted for around 14 days. Following period i experienced continualled short term memory loss, hallucinations of seeing stars, skin irritated rash, shortness of breath &

45 Male on Enbrel 4 + years , My condition is all but gone and I really use no other meds now. Expect a dry cough , Poor night vision ,Memory loss ,and in some cases (345) amniesia. IHAVE noticed a difficulty in learning new&am

8 day ago I had an endoscopy where they used Versed. Since then I have had a horrible time with short term memory. I have had episodes of feeling agressive, angry and verbally hostile and seemed to be 'out of control'.&a

MEMORY IMPAIRMENT Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate
Condition: Cancer
Intervention: Drug: Methotrexate
Outcome Measures: Incidence of success (achieving an end infusion peripheral blood Methotrexate concentration between 50-80 μM);   Incidence of nephrotoxicity;   Incidence of neurotoxicity;   Incidence of mucositis;   Incidence of hepatoxicity;   Incidence of myelosuppression
2 Unknown  Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine
Condition: Lymphoma
Interventions: Drug: Methotrexate and temozolomide;   Drug: Methotrexate , procarbazine ,vincristine ,cytarabine
Outcome Measures: Progression-free survival;   Overall survival:median and overall survival;   Response rates;   Toxicity;   Late toxicity
3 Not yet recruiting The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade
Condition: ALOPECIA AREATA
Intervention: Drug: Methotrexate
Outcome Measures: OUTCOME MESURE;   SECONDARY OUTCOME MEASURE
4 Recruiting A Phase 2b/3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Methotrexate in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate or to Any Disease-Modifying Antirheumatic Drug
Condition: Rheumatoid Arthritis (RA)
Interventions: Drug: masitinib;   Drug: Methotrexate
Outcome Measures: ACR50;   ACR
5 Not yet recruiting The Effects of Methotrexate Therapy on ST Segment Elevation MYocardial InfarctionS (TETHYS Trial)
Condition: Myocardial Infarction
Interventions: Drug: Methotrexate;   Drug: Riboflavin
Outcome Measures: Area under the curve of creatine kinase;   Area under the curve for creatine kinase MB fraction and troponin I high sensitive;   Compare the peaks of CK, CK-MB and troponin I ultra-sensitive;   Compare the levels of high-sensitivity C-reactive protein at admission, after 72 hours and after 3 months;   Compare the levels of erythrocyte sedimentation rate on admission and after 72 hours;   Compare B-type natriuretic peptide (BNP) levels on admission, after 72 hours and after 3 months;   Compare the "TIMI frame count" of the culprit artery;   Compare the Killip score on admission and after 72 hours;   Assess ventricular ejection fraction with transthoracic echocardiography during the first 72 hours after 3 months;   Assess mortality at 3 months;   Evaluate reinfarction in 3 months;   Rate side effects
6 Not yet recruiting VACcination In Methotrexate Treated Rheumatoid Arthritis Patients
Condition: Rheumatoid Arthritis
Interventions: Biological: Prevenar 13;   Biological: Pneumo23;   Drug: Methotrexate
Outcome Measures: rate of immunological positive answer 1 month after antipneumococcal vaccination by the conjugated vaccine Prevenar13 ® in patients suffering from rheumatoid polyarthritis.;   Number of patients in each group who will know fully immunological answer to 5 interest serotypes after the first antipneumococcal vaccination (Prevenar13);   Number of patients in each group who will know an immunological answer to 13 serotypes after the first antipneumococcal vaccination (Prevenar13);   Number of patients who will know a fully immunological answer (13 serotypes of vaccine) after a antipneumococcal revaccination with Pneumo 23.;   Number of patients who will suffer from adverse events in relation with the antipneumococcal vaccination;   Frequency of occurence of disease spurts from the first vaccination until the end of the study;   occurence of the pneumococcal disease from the first vaccination to the end of the study.
7 Recruiting Will the Use of Glucarpidase After Methotrexate Treatment Allow More Patients With Bone Sarcoma to Have Fewer Side Effects and Receive Subsequent Chemotherapy on Time?
Conditions: Osteosarcoma;   Spindle Cell Sarcoma of Bone
Interventions: Drug: Glucarpidase;   Drug: Methotrexate;   Drug: Folinic Acid
Outcome Measures: Estimate of the difference in proportions of patients ready to receive chemotherapy on Day 15 of each chemotherapy cycle comparing standard rescue and glucarpidase+standard rescue;   To investigate whether glucarpidase rescue after high-dose Methotrexate reduces the incidence of Methotrexate associated adverse effects;   Plasma Methotrexate concentration;   Incidence of glucarpidase related adverse effects;   Number of days required in hospital per cycle;   Assessment of quality of life;   Serum anti-glucarpidase IgG levels following glucarpidase administration;   To investigate whether glucarpidase rescue after high-dose Methotrexate reduces the severity of Methotrexate associated adverse effects;   To investigate whether glucarpidase rescue after high-dose Methotrexate reduces the duration of Methotrexate associated adverse effects;   Plasma DAMPA concentration;   Total dose of folinic acid rescue required per cycle
8 Not yet recruiting Methotrexate for Central Serous Chorioretinopathy Treatment Trial
Condition: Central Serous Chorioretinopathy
Interventions: Drug: Methotrexate;   Drug: Delayed treatment
Outcome Measure: Optical Coherence Tomography indicating the level of central serous detachment
9 Recruiting Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Conditions: Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
Interventions: Drug: tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
Outcome Measures: Incidence of severe (grade 3-4) mucositis graded according to the World Health Organization (WHO) grading scale;   Time to neutrophil engraftment;   Time to platelet engraftment;   Incidence of acute GVHD;   Length of hospitalization;   Use of total parenteral nutrition (TPN);   Overall survival defined by Center for International Blood and Marrow Transplant Research (CIBMTR) criteria for individual diseases;   Progression-free survival defined by CIBMTR criteria for individual diseases;   Incidence of chronic GVHD;   Length of time on continuous infusion narcotics;   Incidence of infection;   Incidence of hepatotoxicity;   Incidence of nephrotoxicity;   Incidence of pulmonary toxicity
10 Recruiting Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease
Condition: Graft vs Host Disease
Interventions: Drug: Tacrolimus;   Drug: Cyclosporine;   Drug: Methotrexate
Outcome Measures: incidence of grade II-IV acute graft versus host disease;   incidence of infection;   incidence of adverse drug reactions
11 Recruiting Methotrexate Treatment for Ectopic Pregnancy
Condition: Ectopic Pregnancy
Interventions: Procedure: Single-dose Methotrexate;   Procedure: Two-dose Methotrexate protocol
Outcome Measure: treatment success
12 Recruiting Initial Treatment With Golimumab in Early PsA
Condition: Psoriatic Arthritis
Interventions: Drug: golimumab;   Drug: Methotrexate
Outcome Measures: Percentage of patients achieving DAS remission response criteria;   Number of Participants with Adverse Events;   Number of patients fulfilling Minimal Disease activity criteria and other outcome measurements
13 Recruiting Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Conditions: Gestational Trophoblastic Tumor;   Hydatidiform Mole;   Low Risk Metastatic Gestational Trophoblastic Tumor;   Uterine Choriocarcinoma
Interventions: Drug: leucovorin calcium;   Biological: dactinomycin;   Drug: Methotrexate;   Procedure: quality-of-life assessment
Outcome Measures: Complete response vs treatment failure;   Severity of adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4;   Overall QOL
14 Recruiting A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA
Condition: Rheumatoid Arthritis
Interventions: Drug: Methotrexate;   Drug: ENIA11;   Drug: Placebo
Outcome Measure: ACR20 responder at last treatment visit
15 Recruiting Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia
Condition: Large Granular Lymphocytes Leukemia
Interventions: Drug: Methotrexate;   Drug: Cyclophosphamide
Outcome Measures: Complete response (CR);   overall response rate (ORR);   Hematological partial response (PR);   Progressive disease;   Time-to-relapse;   Molecular remission;   Adverse events rate;   Compliance;   relationship between the response to treatment and the phenotypic subtype
16 Recruiting Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study
Condition: Rheumatoid Arthritis
Interventions: Drug: Methotrexate plus sulfasalazine;   Drug: Leflunomide
Outcome Measures: MRI synovitis score;   MRI bone marrow edema score;   MRI erosion score;   US synovitis score;   clinical outcomes
17 Recruiting A Study on the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous RoActemra/Actemra (Tocilizumab) With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra];   Drug: Methotrexate;   Drug: placebo
Outcome Measures: Change in disease activity (DAS28) scores;   Change in bone erosion scores for patients in the MRI substudy;   Percentage of patients with a >/= 1.2 worsening in DAS28 between Week 24 and Weeks 40 and 52;   Percentage of patients achieving DAS 28 <2.6 and DAS28 </= 3.2 at Weeks 40 and 52;   Percentage of patients achieving ACR20/50/70 responses at Weeks 40 and 52;   Safety: Incidence of adverse events
18 Recruiting Methotrexate in the Treatment of Chronic Idiopathic Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Methotrexate (Novatrex ®) + anti-H1;   Drug: Placebo + anti-H1
Outcome Measures: Number of patients with complete remission of urticaria at 18 weeks;   Tolerance : clinical and biological safety;   Efficacy of the treatment in improving symptoms : pruritus;   Persistency of the complete remission at 26 weeks;   Efficacy of the treatment in improving symptoms : outbreaks by week;   Efficacy of the treatment in improving symptoms : duration of lesions;   Efficacy of the treatment in improving quality of life;   Efficacy of the treatment in improving quality of sleep;   Efficacy of the treatment in improving facial/cervical urticarial lesions
19 Recruiting High-dose Methotrexate and Liposomal Cytarabine in Treating Patients With CNS Metastases From Breast Cancer
Conditions: Central Nervous System Metastases;   Leptomeningeal Metastases;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tumors Metastatic to Brain
Interventions: Drug: Methotrexate;   Drug: liposomal cytarabine;   Other: quality-of-life assessment;   Other: questionnaire administration
Outcome Measures: Progression-free survival (PFS);   Cancer Therapy Evaluation Program (CTEP) Common Toxicity Criteria grade 3+ neurological and systemic toxicity that persists following dose reductions or schedule modifications;   Overall survival;   Duration of response;   Cytologic response as measured by CSF cytology (positive or negative for malignant cells);   FACT-Brain (Br) total score and subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, symptom index) using standard scoring
20 Not yet recruiting Low-dose Methotrexate for Reduction GINA 5 Medications in Chronic Severe Asthma
Condition: Low Dose Methotrexate in Severe Chronic Asthma
Interventions: Drug: Methotrexate;   Drug: Placebo
Outcome Measures: At least 50% reduction in total dosage of GINA step 5 medications;   clinically significant changes in clinimetric scores